MMAS-8 SCORE ASSESSMENT OF THERAPY ADHERENCE TO GLYCEMIC CONTROL OF PATIENTS WITH TYPE 2 DIABETES MELLITUS, TANJUNG PURWOKERTO, JAVA, INDONESIA (OCTOBER 2018)

Publons ID	(not set)
Wos ID	WOS:000745280800001
Doi	
Title	MMAS-8 SCORE ASSESSMENT OF THERAPY ADHERENCE TO GLYCEMIC CONTROL OF PATIENTS WITH TYPE 2 DIABETES MELLITUS, TANJUNG PURWOKERTO, JAVA, INDONESIA (OCTOBER 2018)
First Author	
Last Author	
Authors	Gumilas, NSA; Harini, IM; Samodro, P; Ernawati, DA;
Publish Date	JUN 2021
Journal Name	SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH
Citation	1
Abstract	Diabetes mellitus (DM) type 2, a metabolic disease caused by insulin resistance, remains a global health problem. Glycated hemoglobin (HbA1c) level is used to evaluate diabetes therapy, and a variety of factors influence HbA1c level, one of which is therapy adherence. A cross-sectional study of type 2 diabetes mellitus (DM2) patients (n = 92) at the Primary Health Facility, Tanjung Purwokerto, Indonesia was conducted to evaluate HbA1c levels and therapy adherence using an Indonesian language 8-item Morisky Medication Adherence Scale (MMAS-8) questionnaire. No single sociodemographic characteristic, (certain) co-morbidity or vitamins/iron supplementation was significantly associated with either of the two parameters. Correlations were observed between treatment adherence and age (r = 0.221, p-value = 0.034), and between therapy adherence and HbA1c levels (r =-0.221, p-value = 0.035). Construction of a receiver operating characteristic curve demonstrated that MMAS-8 score was not a reliable predictor of therapy adherence (area under curve = 0.58, 95% confidence interval (CI): 0.46-0.70), using HbA1c level <7% as the reference standard. In conclusion, reliance on MMAS system as the sole predictor of therapy adherence in DM2 patients should be considered with caution.
Publish Type	Journal
Publish Year	2021
Page Begin	359
Page End	370
Issn	0125-1562
Eissn	
Url	https://www.webofscience.com/wos/woscc/full-record/WOS:000745280800001
Author	Dr dr NUR SIGNA AINI GUMILAS, S.Ked, M.Biotek.